Retrospective Chart Review to Evaluate the Safety Profile of Ceftobiprole in Patients With Impaired Hepatic or Renal Function or Immunosuppression
Latest Information Update: 11 Jul 2023
At a glance
- Drugs Ceftobiprole medocaril (Primary)
- Indications Bacteraemia; Community-acquired pneumonia; Nosocomial pneumonia; Skin and soft tissue infections
- Focus Adverse reactions
- Acronyms RETRACE
- Sponsors Correvio
Most Recent Events
- 06 Jul 2023 Status changed from recruiting to completed.
- 24 Nov 2022 Planned End Date changed from 1 Dec 2022 to 30 Jun 2023.
- 24 Nov 2022 Planned primary completion date changed from 1 Dec 2022 to 30 Jun 2023.